Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 05, 2021 6:04pm
339 Views
Post# 34094511

Kswdelux….listen , then comment.

Kswdelux….listen , then comment.

Kswdelux
you went off on a rant, prefeced by " you did not yet listen to Conference call."
Please do yourself & those reading a huge favour. Listen to the CC.
Rather than micro- dissecting previous NRs , like an arm chiar lawyer. Get as best informed as you can.
Some of your questions will be answered, some won't. At least your feedback will be based on best case information.
FYI
News releases are boiled down to fit into as small a message as possible. 
Matts said  today
" Aware-1 bio marker data exceeded expectations, with statistical significance".
Today's CC  was one of the most technical.I have listened to.
The business development side lacking in details, other than multiple collaborations are on- going.
Bittom line.
When the news lights up regarding any deal with $$ attatched Onc SP will go up.
Neil then, as RW says.....another brick in the wall

 

 

<< Previous
Bullboard Posts
Next >>